SG11202105736QA - Combination therapy for the treatment of cancer - Google Patents
Combination therapy for the treatment of cancerInfo
- Publication number
- SG11202105736QA SG11202105736QA SG11202105736QA SG11202105736QA SG11202105736QA SG 11202105736Q A SG11202105736Q A SG 11202105736QA SG 11202105736Q A SG11202105736Q A SG 11202105736QA SG 11202105736Q A SG11202105736Q A SG 11202105736QA SG 11202105736Q A SG11202105736Q A SG 11202105736QA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- combination therapy
- therapy
- combination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862784084P | 2018-12-21 | 2018-12-21 | |
PCT/US2019/068153 WO2020132633A1 (en) | 2018-12-21 | 2019-12-20 | Combination therapy for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202105736QA true SG11202105736QA (en) | 2021-06-29 |
Family
ID=71102908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202105736QA SG11202105736QA (en) | 2018-12-21 | 2019-12-20 | Combination therapy for the treatment of cancer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220041751A1 (en) |
EP (1) | EP3897650A4 (en) |
JP (1) | JP2022515128A (en) |
KR (1) | KR20210107023A (en) |
CN (1) | CN113271948A (en) |
AU (1) | AU2019406210A1 (en) |
BR (1) | BR112021011493A2 (en) |
CA (1) | CA3121807A1 (en) |
IL (1) | IL284162A (en) |
MA (1) | MA54559A (en) |
MX (1) | MX2021007554A (en) |
PH (1) | PH12021551276A1 (en) |
SG (1) | SG11202105736QA (en) |
WO (1) | WO2020132633A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3773551A4 (en) * | 2018-03-27 | 2022-03-23 | Board of Regents, The University of Texas System | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations |
JP2022527499A (en) * | 2019-03-29 | 2022-06-02 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Compounds with antitumor activity against cancer cells with HER2 exon 21 insertion |
TW202330040A (en) * | 2021-10-14 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Use of anti-her2 antibody drug conjugate and tyrosine kinase inhibitor in the preparation of drugs for treating tumors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017363199B2 (en) * | 2016-11-17 | 2023-08-17 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations |
EP3773551A4 (en) * | 2018-03-27 | 2022-03-23 | Board of Regents, The University of Texas System | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations |
CN112423745A (en) * | 2018-06-25 | 2021-02-26 | 光谱制药有限公司 | Compositions of bosutinib with anti-HER 1, anti-HER 2, or anti-HER 4 antibodies and methods of use thereof |
-
2019
- 2019-12-20 MA MA054559A patent/MA54559A/en unknown
- 2019-12-20 WO PCT/US2019/068153 patent/WO2020132633A1/en unknown
- 2019-12-20 AU AU2019406210A patent/AU2019406210A1/en active Pending
- 2019-12-20 US US17/416,227 patent/US20220041751A1/en active Pending
- 2019-12-20 MX MX2021007554A patent/MX2021007554A/en unknown
- 2019-12-20 KR KR1020217020491A patent/KR20210107023A/en unknown
- 2019-12-20 CN CN201980087140.8A patent/CN113271948A/en active Pending
- 2019-12-20 JP JP2021535545A patent/JP2022515128A/en active Pending
- 2019-12-20 BR BR112021011493-9A patent/BR112021011493A2/en not_active Application Discontinuation
- 2019-12-20 CA CA3121807A patent/CA3121807A1/en active Pending
- 2019-12-20 EP EP19899260.4A patent/EP3897650A4/en active Pending
- 2019-12-20 SG SG11202105736QA patent/SG11202105736QA/en unknown
-
2021
- 2021-05-31 PH PH12021551276A patent/PH12021551276A1/en unknown
- 2021-06-17 IL IL284162A patent/IL284162A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210107023A (en) | 2021-08-31 |
JP2022515128A (en) | 2022-02-17 |
PH12021551276A1 (en) | 2021-12-06 |
EP3897650A1 (en) | 2021-10-27 |
EP3897650A4 (en) | 2022-12-28 |
AU2019406210A1 (en) | 2021-06-24 |
MX2021007554A (en) | 2021-08-11 |
CA3121807A1 (en) | 2020-06-25 |
IL284162A (en) | 2021-08-31 |
WO2020132633A1 (en) | 2020-06-25 |
CN113271948A (en) | 2021-08-17 |
BR112021011493A2 (en) | 2021-09-14 |
US20220041751A1 (en) | 2022-02-10 |
MA54559A (en) | 2022-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281256A (en) | Combination therapy for the treatment of triple-negative breast cancer | |
IL267795A (en) | Combination therapy for the treatment of cancer | |
HK1247129A1 (en) | Combination therapy for the treatment of cancer | |
HK1251475A1 (en) | Combination therapy for the treatment of cancer | |
IL280337A (en) | Lag-3 combination therapy for the treatment of cancer | |
ZA202206743B (en) | Therapy for the treatment of cancer | |
IL281845A (en) | Combination therapy for the treatment of cancer | |
IL284162A (en) | Combination therapy for the treatment of cancer | |
IL275949A (en) | Combination therapy for treating or preventing cancer | |
IL264589A (en) | Combination therapy for the treatment of pancreatic cancer | |
IL281439A (en) | Combination therapy for treating blood cancer | |
IL266993A (en) | Combination therapy for the treatment of cancer | |
IL281281A (en) | Combination therapy for the treatment of prostate cancer | |
IL275981A (en) | Combination therapies for the treatment of breast cancer | |
IL276073A (en) | Combination therapy for treating or preventing cancer | |
IL276074A (en) | Combination therapy for treating or preventing cancer | |
IL275860A (en) | Combination therapy for treating or preventing cancer | |
SG11202100571TA (en) | Anti-lypd3 car t-cell therapy for the treatment of cancer | |
IL263905A (en) | Combination therapy of cancer | |
IL253642A0 (en) | Combination therapy for the treatment of cancer | |
IL281782A (en) | Pharmaceutical combination for the treatment of cancer | |
GB201808636D0 (en) | Combination therapy for treating or preventing cancer | |
GB201808628D0 (en) | Combination therapy for treating or preventing cancer | |
GB201808631D0 (en) | Combination therapy for treating or preventing cancer | |
GB201808632D0 (en) | Combination therapy for treating or preventing cancer |